Selpercatinib User Reviews & Ratings
Brand names: Retevmo
Selpercatinib has an average rating of 10.0 out of 10 from a total of 5 reviews on Drugs.com. 100% of reviewers reported a positive experience, while 0% reported a negative experience.
Condition | Avg. Rating | Reviews | Compare |
---|---|---|---|
Non Small Cell Lung Cancer | 4 reviews for Non Small Cell Lung Cancer | 64 medications | |
Thyroid Cancer | 1 reviews for Thyroid Cancer | 25 medications |
- Sar...
- Taken for 1 to 2 years
- October 26, 2023
Selpercatinib for Non Small Cell Lung Cancer "Was diagnosed in Jan 2020 at 45 years old with stage 3b NSCLC. A year ago, it advanced to stage 4 when it spread to my bones (shoulder, spine, and pelvis). This is when I started taking Retevmo. I take 160 mg twice daily, and as of now, my cancer is stable. The main thing is, I had a lot of stomach discomfort and I developed enteritis a couple of months after I started taking it. Three months ago, I changed my diet and how I eat, and since then, no more stomach burning. Overall, it has been a positive experience. I feel great and live a very active life. I hope it continues to work."
- Dan...
- Taken for 2 to 5 years
- March 5, 2023
For Thyroid Cancer "Diagnosed with MTC 8/2020. Rx initiated 11/2020. One month later, primary nodule in thyroid and larger nodules in lung decreased in size by ~50%. Little or no reduction subsequently, but calcitonin and CEA continued to drop until in normal range (big drop first few months!). Started with 320 mg, reduced after 3-4 months to 240 mg, then to 160 mg (80 mg 2x daily). Condition stable as of 01/2023. Early side effects were abdominal pain and slight leg swelling in one leg. Pain went away after dosage reduced. Swelling diminished. Doctor says some from initial trial stable four years on. I can’t find any data, though, other than for trials that led to initial approval, which only refer to efficacy after 6 months. I wish I could find more new data, but am very happy with results to date, and I’m hoping stability continues … UNTIL A CURE IS FOUND! Keep working, researchers. You don’t know us, but we’re counting on you. Thank you."
- Lor...
- Taken for 1 to 6 months
- November 21, 2023
Selpercatinib for Non Small Cell Lung Cancer "Diagnosed NSCLC stage 4B March 2023. Began full dosage of Retevmo May 2023. First PET scan in August showed NED. Truly amazing! Now on 40 mg twice a day."
- Din...
- Taken for less than 1 month
- February 1, 2021
Selpercatinib for Non Small Cell Lung Cancer "Retevmo just makes me feel tired."
Are you taking this medicine?
Your review helps others make informed decisions.More about selpercatinib
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Selpercatinib for Non Small Cell Lung Cancer "I believe Retevmo to be a major part of why I am still alive today. Not expected to live to the end of 2020, I was given Retevmo by my cancer doctors in August of that year. Here I am now, a much more functioning person, in the workforce, and enjoying every day as I can! I take Retevmo 160mg twice daily, twelve hours apart (breakfast and dinner). Thank you, Eli Lilly, for sharing this drug with those who are fortunate enough to be able to take it."